In a rheumatoid arthritis patient on methotrexate and leflunomide who cannot taper steroids and requires 5 mg dexamethasone daily, what is the appropriate management and can tofacitinib be added?

Adding Tofacitinib to Methotrexate and Leflunomide in Steroid-Dependent RA

Yes, you can add tofacitinib to this patient's regimen, but you must first discontinue leflunomide due to safety concerns about combining multiple immunosuppressants. The patient has failed conventional synthetic DMARDs (csDMARDs) and requires chronic steroids, meeting criteria for escalation to biologic or targeted synthetic DMARDs (tsDMARDs) like tofacitinib.

Treatment Algorithm

Step 1: Assess Current Failure

This patient has:

• Failed methotrexate + leflunomide combination (inadequate response)
• Steroid dependency (cannot taper below 5mg daily)
• Meets criteria for Phase II treatment escalation per EULAR guidelines 1

Step 2: Discontinue Leflunomide Before Adding Tofacitinib

Critical safety consideration: Tofacitinib should NOT be combined with potent immunosuppressants like leflunomide 2. The guidelines explicitly state tofacitinib can be used with methotrexate but should not be combined with other potent immunosuppressants 2.

Leflunomide washout procedure 3:

• Administer cholestyramine 8g three times daily for 11 days (need not be consecutive)
• OR activated charcoal 50g four times daily for 11 days
• Verify plasma levels of active metabolite (M1) <0.02 mg/L before starting tofacitinib
• Without washout, leflunomide metabolites persist for up to 2 years

Step 3: Initiate Tofacitinib + Methotrexate

Recommended regimen:

• Tofacitinib 5mg twice daily with continued methotrexate 1, 4, 5
• Continue methotrexate at current optimized dose (should be 20-25mg weekly, parenteral if oral not tolerated) 6, 4
• Evidence shows tofacitinib + methotrexate superior to either monotherapy 5, 7, 8

Step 4: Steroid Tapering Strategy

Once disease control achieved with tofacitinib + methotrexate:

• Begin tapering steroids after 3 months if showing improvement 1
• Target complete discontinuation within 6 months 1, 9
• Reassess at 3 months; if no improvement, consider switching to biologic DMARD 1

Why This Approach

EULAR treatment algorithm 1 positions tofacitinib after csDMARD failure:

• Phase I: Methotrexate ± other csDMARDs (failed in this patient)
• Phase II: Add biologic DMARD OR tofacitinib when poor prognostic factors present
• Steroid dependency indicates inadequate disease control, warranting escalation

Tofacitinib efficacy data 5:

• ACR20 response: 52-62% in csDMARD-inadequate responders
• Works synergistically with methotrexate 7, 8
• Effective across all methotrexate dose ranges 8

Recent evidence 10 shows tofacitinib may even outperform methotrexate in DMARD-naive patients, supporting its use in this more refractory case.

Critical Safety Monitoring

Before starting tofacitinib:

• Complete blood count, liver enzymes, creatinine
• Tuberculosis screening (interferon-gamma release assay or PPD)
• Hepatitis B/C serology
• Lipid panel 2, 4

Ongoing monitoring:

• CBC every 1-3 months (watch for lymphopenia, anemia) 2
• Liver enzymes every 1-3 months 2
• Hold tofacitinib if hemoglobin drops significantly 2
• Avoid live vaccines 2

Common Pitfalls to Avoid

1. Do NOT combine tofacitinib with leflunomide - This violates safety guidelines and increases infection/hepatotoxicity risk 2

2. Do NOT skip leflunomide washout - Active metabolites persist for months and can cause serious toxicity when combined with tofacitinib 3

3. Do NOT continue chronic steroids indefinitely - The 2021 ACR guidelines 4, 9 strongly recommend against glucocorticoids ≥3 months; taper aggressively once tofacitinib takes effect

4. Do NOT use inadequate methotrexate dosing - Ensure methotrexate optimized to 20-25mg weekly before declaring failure 6, 4; consider switching to subcutaneous if oral not tolerated

Alternative if Tofacitinib Unavailable

If tofacitinib not accessible, the EULAR algorithm 1 recommends:

• TNF inhibitor (adalimumab, etanercept, others) + methotrexate
• OR non-TNF biologic (abatacept, tocilizumab) + methotrexate
• These are preferred over continuing failed csDMARD combinations with chronic steroids

The combination of methotrexate + leflunomide has shown efficacy in some studies 11, 12, 13, 14, but this patient has already failed this combination, necessitating escalation to biologic/targeted therapy rather than continuing the same failed regimen with chronic steroids.